Objective To find out the advantages and disadvantages of medical quality and provide a scientific basis for more scientific and fine medical quality management by comprehensively evaluating the medical quality of surgical departments of 3 Grade class A hospital.Methods Through literature research and expert consulting,combined with the actual conditions of the hospital,the evaluation indicators were determined.Weights were objectively assigned to the evaluation indicators with the entropy weight method and the surgical medical quality was comprehensively evaluated with non-integer rank WRSR.Results Seen from medical service capacity,the entropy weights of RW ≥2 and Level-4 surgery are relatively big;seen from the efficiency of medical service,the entropy weights of the time consumption index and cost consumption index are relatively big;seen from the safety of medical services,the entropy weight of postoperative death in the perioperative period is the biggest.The results of grad-ing of medical quality evaluation of surgical departments indicated that joint surgery,spinal surgery,neurosurgery,and thoracic surgery were"good"departments;15 departments,such as obstetrics,traumatic orthopedics,ENT,and gynecology,were"gen-eral"departments;and cardiac surgery and stomatology were"poor"departments.Conclusion The medical quality of surgical departments was comprehensively evaluated with non-integer rank WRSR.The evaluation results were consistent with the actual conditions of the hospital.Surgical departments should take targeted measures and make rectifications according to the results of the evaluation;and the hospital should reasonably allocate medical resources and make related policies with evaluation results combined with the needs of the development of departments.

Objective To find out the advantages and disadvantages of medical quality and provide a scientific basis for more scientific and fine medical quality management by comprehensively evaluating the medical quality of surgical departments of 3 Grade class A hospital.Methods Through literature research and expert consulting,combined with the actual conditions of the hospital,the evaluation indicators were determined.Weights were objectively assigned to the evaluation indicators with the entropy weight method and the surgical medical quality was comprehensively evaluated with non-integer rank WRSR.Results Seen from medical service capacity,the entropy weights of RW ≥2 and Level-4 surgery are relatively big;seen from the efficiency of medical service,the entropy weights of the time consumption index and cost consumption index are relatively big;seen from the safety of medical services,the entropy weight of postoperative death in the perioperative period is the biggest.The results of grad-ing of medical quality evaluation of surgical departments indicated that joint surgery,spinal surgery,neurosurgery,and thoracic surgery were"good"departments;15 departments,such as obstetrics,traumatic orthopedics,ENT,and gynecology,were"gen-eral"departments;and cardiac surgery and stomatology were"poor"departments.Conclusion The medical quality of surgical departments was comprehensively evaluated with non-integer rank WRSR.The evaluation results were consistent with the actual conditions of the hospital.Surgical departments should take targeted measures and make rectifications according to the results of the evaluation;and the hospital should reasonably allocate medical resources and make related policies with evaluation results combined with the needs of the development of departments.

Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults and is poorly controlled. Previous studies have shown that both macrophages and angiogenesis play significant roles in GBM progression, and co-targeting of CSF1R and VEGFR is likely to be an effective strategy for GBM treatment. Therefore, this study developed a novel and selective inhibitor of CSF1R and VEGFR, SYHA1813, possessing potent antitumor activity against GBM. SYHA1813 inhibited VEGFR and CSF1R kinase activities with high potency and selectivity and thus blocked the cell viability of HUVECs and macrophages and exhibited anti-angiogenetic effects both in vitro and in vivo. SYHA1813 also displayed potent in vivo antitumor activity against GBM in immune-competent and immune-deficient mouse models, including temozolomide (TMZ) insensitive tumors. Notably, SYHA1813 could penetrate the blood-brain barrier (BBB) and prolong the survival time of mice bearing intracranial GBM xenografts. Moreover, SYHA1813 treatment resulted in a synergistic antitumor efficacy in combination with the PD-1 antibody. As a clinical proof of concept, SYHA1813 achieved confirmed responses in patients with recurrent GBM in an ongoing first-in-human phase I trial. The data of this study support the rationale for an ongoing phase I clinical study (ChiCTR2100045380).